IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Takeda Launches First-in-Class Narcolepsy Drug ORZEYFUL in Japan and China
Takeda announced that ORZEYFUL (oveporexton), its first-in-class oral orexin receptor 2 (OX2R) agonist, is now commercially available in Japan and China to...
🟢 Healthcare ETF (IYH) is trading 5.7% up in pre-market after UnitedHealth raised 2026 adjusted earnings outlook
IYH is trading at $77.35, up +5.73%, as UnitedHealth beat Q3 expectations and raised its 2026 adjusted earnings outlook to at least $20.50 per share. - The...
UnitedHealth Raises Earnings Forecast After Optum-Fueled Q3 Beat
UnitedHealth Group reported third-quarter adjusted earnings of $7.15 per share, above the analyst consensus of $6.92. Revenue was $101.8 billion, compared with...
🟢 Healthcare ETF (IYH) is trading 3% up in pre-market after UnitedHealth raises 2026 profit outlook
IYH is trading at $74.75 (+3.03%), with UnitedHealth’s strong results likely serving as a healthcare-sector catalyst. - UnitedHealth reported adjusted...
Humana Soars 15% on 2027 Ratings, With 95% in 4+ Star Plans
Humana shares rose more than 15% in premarket trading after the insurer reported a sharp improvement in its Medicare Advantage (MA) Star Ratings for the 2027...
Pfizer Wins FDA Approval for Chemotherapy-Free TUKYSA Maintenance in HER2-Positive Breast Cancer
The U.S. Food and Drug Administration (FDA) approved Pfizer’s TUKYSA (tucatinib), in combination with trastuzumab and pertuzumab, for maintenance treatment of...
Eli Lilly reports EloraTZP's 23.3% average weight loss in Phase 2
Eli Lilly reported positive Phase 2 results for EloraTZP, its next-generation obesity drug. Patients taking the drug lost an average of 23.3% of their body...
Eli Lilly's Oral Foundayo Shows Cardiovascular Safety in Largest Diabetes Trial
Eli Lilly said its oral GLP-1 drug Foundayo demonstrated cardiovascular non-inferiority in the largest diabetes trial conducted to date. Cardiovascular safety...
Novo Nordisk Licenses Weekly Oral Obesity Drug in Up-to-$2.6B Hengrui Deal
Novo Nordisk has signed a licensing agreement with Chinese pharmaceutical company Hengrui Pharma for HRS-1596, an early-stage, once-weekly oral obesity...
GRAIL Wins 7-2 FDA Panel Support for Galleri Approval
An advisory committee to the U.S. Food and Drug Administration (FDA) voted 7-2 in favor of GRAIL’s premarket approval application for its Galleri multi-cancer...
🔴 Healthcare ETF (IYH) is trading 3.19% down in pre-market after Trump rejected Iran’s Hormuz proposal
IYH is trading at $70.13, down 3.19% in pre-market; the decline may reflect broader risk-market weakness following President Trump’s rejection of Iran’s Strait...
Novo Nordisk Signs $1.33B Nanexa Deal for Long-Acting Obesity and Diabetes Drugs
Novo Nordisk has signed a licensing agreement with Swedish drug delivery firm Nanexa worth up to €1.165 billion ($1.33 billion). The deal gives Novo Nordisk...
Eli Lilly Wins FDA Approval for Onswik, Slashing Annual Insulin Injections
The U.S. Food and Drug Administration approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe). This once-weekly basal insulin injection treats...
Ultragenyx Wins FDA Approval for $3.95M Therapy, First for Sanfilippo Syndrome
The U.S. Food and Drug Administration (FDA) granted full approval to Ultragenyx Pharmaceutical's gene therapy, FAYUVI (UX111). This one-time intravenous...
US Treasury shields China pharma deals, protecting $115 billion biotech pipeline
The U.S. Treasury Department is drafting rules to preserve most licensing deals between American pharmaceutical companies and Chinese drug developers. This...
Novo Nordisk signs $1.4B AI drug deal, targeting cardiometabolic diseases
Novo Nordisk and Orbis Medicine launched a drug discovery partnership valued at up to $1.4 billion. The collaboration focuses on developing new treatments for...
GSK acquires Chimagen for $750M, targeting resistant blood cancers
GSK acquired Chimagen to gain full global rights for a preclinical trispecific T-cell therapy. The agreement includes an upfront payment and milestones...
Takeda Secures FDA Priority Review for Psoriasis Drug Zasocitinib
The U.S. Food and Drug Administration (FDA) accepted Takeda’s New Drug Application (NDA) for zasocitinib (TAK-279). The agency granted Priority Review for the...
Akeso Beats Merck’s Keytruda in Lung Cancer Trial, Boosting Survival
Akeso Inc. announced positive overall survival results from its Phase III HARMONi-2 trial for ivonescimab. Researchers presented the data at the World...
BMS and SystImmune Advance Iza-bren to Phase 3, Citing Positive Lung Data
SystImmune and Bristol Myers Squibb announced Phase 1 data for iza-bren (izalontamab brengitecan) at the 2026 World Conference on Lung Cancer. The study...